(NASDAQ: INDV) Indivior's forecast annual revenue growth rate of -0.81% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 129.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.15%.
Indivior's revenue in 2025 is $1,181,000,000.On average, 5 Wall Street analysts forecast INDV's revenue for 2025 to be $133,219,108,099, with the lowest INDV revenue forecast at $124,978,750,897, and the highest INDV revenue forecast at $147,452,452,357. On average, 5 Wall Street analysts forecast INDV's revenue for 2026 to be $137,214,432,803, with the lowest INDV revenue forecast at $131,471,153,541, and the highest INDV revenue forecast at $146,453,621,181.
In 2027, INDV is forecast to generate $144,580,812,726 in revenue, with the lowest revenue forecast at $138,088,410,082 and the highest revenue forecast at $152,072,046,546.